楤木皂苷A在大鼠体内的组织分布研究

Tissue distribution of araloside A in rats

楤木皂苷A为太白楤木中的主要活性成分之一。该文通过建立SD大鼠主要脏器中楤木皂苷A的LC-MS/MS分析方法,同时口服灌胃楤木皂苷A 50 mg·kg^(-1),测定大鼠主要脏器(心、肝、脾、肺、肾、脑)中的楤木皂苷A含量,探讨体内的组织分布特征。结果显示楤木皂苷A在SD大鼠主要脏器中的方法学考察符合要求,口服灌胃楤木皂苷A 50 mg·kg^(-1),在心、肝、脾、肺、肾、脑组织均有分布且在1 h或2 h时达到最大值。在给药后不同时间点楤木皂苷A的组织分布情况不同:给药20min各组织含量:肝>心>脾>肺>肾>脑;给药1 h各组织含量:肝>脾>肾>肺>心>脑;给药2 h各组织含量:肝>肾>心>脾>肺>脑;给药4 h各组织含量:肾>肝>脾>心>肺>脑;给药8 h各组织含量:脾>心>肝>肾>肺>脑。提示楤木皂苷A主要分布于肝组织,这也与太白楤木常用于治疗肝脏疾病具有一定的相关性。另外,楤木皂苷A在脑组织中虽含量低但有明显分布,提示药物可能会透过血脑屏障,也为楤木皂苷A在脑组织的研究提供了依据。

Araloside A is one of the main active ingredients of Aralia taibaiensis. In this study, HPLC-MS/MS analysis method of araloside A in the main organs of SD rats was established. At the same time, the content of araloside A in the main organs （ heart, liv- er, spleen, lung, kidney, brain） after oral administration with araloside A （50 mg·kg^-1） were determined to explore the tissue dis- tribution characteristics of araloside A in vivo. The results showed that the methodological study of araloside A in the main organs of SD rats met the requirements, araloside A distributed in heart, liver, spleen, lung, kidney and brain tissues reached peak at 1 h or 2 h af- ter oral administration with 50 mg ~ kg-~. The distributions of araloside A at different time points after administration were distinct as follows ： the content of araloside A at 20 min ：liver 〉 heart 〉 spleen 〉 lung 〉 kidney 〉 brain ; the content of araloside A at 1 h ： liver 〉 spleen 〉 kidney 〉 lung 〉 heart 〉 brain ; the content of araloside A at 2 h ： liver 〉 kidney 〉 heart 〉 spleen 〉 lung 〉 brain ; the content of araloside A at 4 h ： kidney 〉 liver 〉 spleen 〉 bean 〉 lung 〉 brain ; the content of araloside A at 8 h ： spleen 〉 heart 〉 liver 〉 kidney 〉 lung 〉 brain. Therefore, araloside A was mainly distributed in liver tissue, which had a certain correlation with the common use of Ara- lia taibaiensis in the treatment of hepatic disease. In addition, araloside A shows a low content but an obvious distribution in brain tis- sues, which indicates that the drug can pass through blood-brain barrier, and provides the basis for the study of araloside A in brain tissue.